PanImmun

Project Image:
Title of the project:

PanImmun

Teasertext:
Innovative immunotherapy of pancreatic cancer by tumor-specific T cells
Project name:
PanImmun
Start:
01.02.2020
End:
31.07.2022
Project leader:
Dr. Christian Schmees
Project funding:
  • BMWi
Project management:
  • VDI/VDE Innovation + Technik GmbH
Funding reference number:
16KN073254
Description:

In the project, a method for the identification of tumor-specific cytotoxic T cells, without knowledge of the tumor antigens recognized by T cells, is being further developed for use in pancreatic cancer. In addition to tumor-specific, cytotoxic T cells, helper T cells are also identified, produced by gene transfer and tested for tumor reactivity. To demonstrate the tumor reactivity of T cells, a microtumor model system is developed at NMI from pancreatic carcinoma tissue of patients recruited at the University Clinic for General, Visceral and Transplant Surgery Tübingen. This creates a new combination of cellular immunotherapy and diagnostic efficacy testing for pancreatic cancer.

Project partners:
  • TheryCell GmbH, Berlin
  • Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie Tübingen